NOVERA COMPOUNDS

FOXO4-DRI 10mg

10% off, code: PEPTEN
Purity Guarantee

FOXO4-DRI 10mg

Sign in to view pricing and purchase this product.

Log In Sign Up
Quantity Discount (%) Price
1 - 5 — $200.00
6 - 10 10 % $180.00
11 - 20 19 % $162.00
21+ 27 % $146.00

Why choose Novera Compounds peptides

Research-grade Quality

Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.

Documented and traceable

  • Batch number on every vial

  • Published Certificates of Analysis

  • Purity verified by third-party testing

Handled and shipped with care

Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.

About the product

FOX04DRI (10mg) is a synthetic peptide developed for laboratory investigation into cellular aging and regulatory protein interactions. This peptide models interactions associated with cellular senescence pathways in controlled experimental environments. It has a molecular weight of 5358.05 g/mol and is produced using controlled peptide synthesis to ensure consistency and analytical purity suitable for research use.

In laboratory settings, FOX04DRI is typically supplied as a lyophilized powder in a sterile vial, enabling precise preparation according to experimental protocols. Current studies focus on its interaction with proteins involved in cellular stress responses and aging-related biological processes. It is commonly examined in studies exploring signaling patterns linked to senescent cell activity and cellular regulation.

FOX04DRI (10mg) Key Features & Specs

FOX04DRI (10mg) is prepared for use in controlled research environments where consistency and accurate peptide characterization are essential. The FOX04-DRI peptide is frequently included in experimental protocols examining cellular signaling and senescence-related mechanisms.

As part of ongoing FOX04-DRI research, it is used in studies of aging biology and protein interaction models.

  • Subcategory: Longevity & Anti-Aging Peptides
  • Strength: 10 mg
  • CAS: 2460055-10-9
  • Chemical Formula: C₂₂₈H₃₈₈N₈₆O₆₄
  • Molecular Weight: 5358.05 g/mol
  • Peptide Sequence: LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRPPPRRRQRRKKRG
  • Synonyms: FOX04-DRI

For laboratory research use only.

FOX04DRI (10mg) Research Uses

In laboratory settings, FOX04DRI is studied for its role in cellular processes associated with aging. The FOX04-DRI senolytic peptide is frequently examined in experimental models exploring how senescent cells influence tissue function and biological signaling networks.

Researchers conducting FOX04DRI studies often examine how peptides designed to interact with senescence-associated proteins may affect cellular signaling patterns in cultured cells or preclinical systems. These investigations typically focus on cellular communication, molecular regulation, and the biological pathways that influence cell survival and turnover.

FOX04DRI is also used in studies investigating how peptide-based compounds modulate cellular stress responses and aging-related biological markers. These studies aim to improve scientific understanding of senescence-related mechanisms in controlled research settings.

FOX04DRI (10mg) Insights & Observed Findings

Experimental literature on FOX04DRI has evaluated its behavior in controlled laboratory models of cellular senescence. Researchers analyze how peptide exposure influences cellular activity, signaling balance, and molecular markers associated with aging processes.

Published findings often describe experiments using cultured cells or preclinical models under carefully monitored laboratory conditions. Researchers observe changes in cellular behavior, signaling markers, or gene expression patterns following exposure to the peptide.

Some studies investigating the FOX04-DRI senolytic peptide have examined concentration ranges used in in vitro experiments to observe cellular responses. These observations contribute to ongoing scientific exploration of peptide-based approaches to studying senescence biology.

FOX04DRI (10mg) Handling & Storage

FOX04DRI should be handled using standard laboratory procedures appropriate for peptide-based research materials. The lyophilized compound is typically stored at approximately –20°C to help preserve structural integrity before preparation.

Researchers should protect the material from light and moisture, and allow the vial to reach room temperature before opening to minimize exposure to condensation. After reconstitution, use the prepared solution promptly according to experimental protocols.

Careful handling practices are recommended during research to maintain peptide integrity and support consistent laboratory results.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

  1. Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132-147.e16. doi:10.1016/j.cell.2017.02.031
  2. Huang Y, He Y, Makarcyzk MJ, Lin H. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Frontiers in Bioengineering and Biotechnology. 2021;9:677576. doi:10.3389/fbioe.2021.677576
  3. Zhang C, Xie Y, Chen H, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging. 2020;12(2):1272-1284. doi:10.18632/aging.102682
  4. Le HH, Cinaroglu SS, Manalo EC, et al. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine. 2021;73:103646. doi:10.1016/j.ebiom.2021.103646
  5. Bourgeois B, Spreitzer E, Platero-Rochart D, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications. 2025;16(1):5672. doi:10.1038/s41467-025-60844-9